172 related articles for article (PubMed ID: 23064959)
21. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
[TBL] [Abstract][Full Text] [Related]
22. A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer.
Castellan P; Castellucci R; Marchioni M; De Nunzio C; Tema G; Primiceri G; Schips L; Cindolo L
Expert Opin Drug Saf; 2019 Sep; 18(9):759-767. PubMed ID: 31353982
[No Abstract] [Full Text] [Related]
23. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
[TBL] [Abstract][Full Text] [Related]
24. Commentary on "Abiraterone in metastatic prostate cancer without previous chemotherapy." Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. N Engl J Med 2013;368(2):138-48 [Epub 2012 Dec 10]; N Engl J Med 2013;368(6):584.
Trump DL
Urol Oncol; 2013 Nov; 31(8):1846. PubMed ID: 24210085
[TBL] [Abstract][Full Text] [Related]
25. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers.
Bello CL; LaBadie RR; Ni G; Boutros T; McCormick C; Ndongo MN
Cancer Chemother Pharmacol; 2012 Apr; 69(4):991-7. PubMed ID: 22147075
[TBL] [Abstract][Full Text] [Related]
26. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
[TBL] [Abstract][Full Text] [Related]
27. Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate.
Hussaini A; Olszanski AJ; Stein CA; Bosch B; Nemeth P
Cancer Chemother Pharmacol; 2017 Sep; 80(3):479-486. PubMed ID: 28695267
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
Morris MJ; Kelly WK; Slovin S; Ryan C; Eicher C; Heller G; Scher HI
J Urol; 2007 Dec; 178(6):2378-83; discussion 2383-4. PubMed ID: 17936848
[TBL] [Abstract][Full Text] [Related]
29. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.
Scott LJ; Yang LPH; Lyseng-Williamson KA
Drugs Aging; 2012 Mar; 29(3):243-248. PubMed ID: 22372727
[TBL] [Abstract][Full Text] [Related]
30. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
31. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Small EJ; Lance RS; Gardner TA; Karsh LI; Fong L; McCoy C; DeVries T; Sheikh NA; GuhaThakurta D; Chang N; Redfern CH; Shore ND
Clin Cancer Res; 2015 Sep; 21(17):3862-9. PubMed ID: 25925891
[TBL] [Abstract][Full Text] [Related]
32. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.
Nakashima D; Takama H; Ogasawara Y; Kawakami T; Nishitoba T; Hoshi S; Uchida E; Tanaka H
J Clin Pharmacol; 2007 Oct; 47(10):1311-9. PubMed ID: 17652181
[TBL] [Abstract][Full Text] [Related]
33. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
Leibowitz-Amit R; Seah JA; Atenafu EG; Templeton AJ; Vera-Badillo FE; Alimohamed N; Knox JJ; Tannock IF; Sridhar SS; Joshua AM
Eur J Cancer; 2014 Sep; 50(14):2399-407. PubMed ID: 25042152
[TBL] [Abstract][Full Text] [Related]
34. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Fizazi K; De Bono JS; Flechon A; Heidenreich A; Voog E; Davis NB; Qi M; Bandekar R; Vermeulen JT; Cornfeld M; Hudes GR
Eur J Cancer; 2012 Jan; 48(1):85-93. PubMed ID: 22129890
[TBL] [Abstract][Full Text] [Related]
35. Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.
Crawford ED; Shore ND; Petrylak DP; Higano CS; Ryan CJ
Ther Adv Med Oncol; 2017 May; 9(5):319-333. PubMed ID: 28529549
[TBL] [Abstract][Full Text] [Related]
36. Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
Arasaratnam M; Crumbaker M; Bhatnagar A; McKay MJ; Molloy MP; Gurney H
Cancer Chemother Pharmacol; 2019 Jul; 84(1):139-146. PubMed ID: 31081533
[TBL] [Abstract][Full Text] [Related]
37. Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.
Petrioli R; Francini E; Fiaschi AI; Laera L; Miano ST; De Rubertis G; Roviello G
Anticancer Res; 2015 May; 35(5):3097-102. PubMed ID: 25964601
[TBL] [Abstract][Full Text] [Related]
38. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
Agarwal N; Hutson TE; Vogelzang NJ; Sonpavde G
Future Oncol; 2010 May; 6(5):665-79. PubMed ID: 20465382
[TBL] [Abstract][Full Text] [Related]
39. The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6.
Tammara B; Trang JM; Miyamoto G; Kitani M; Brisson J; Bramer SL
J Clin Pharmacol; 2002 May; 42(5):492-500. PubMed ID: 12017343
[TBL] [Abstract][Full Text] [Related]
40. Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate.
Cella D; Li S; Li T; Kheoh T; Todd MB; Basch E
J Community Support Oncol; 2016 Apr; 14(4):148-54. PubMed ID: 27152513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
